trending Market Intelligence /marketintelligence/en/news-insights/trending/9vD6e-P4lolrNw_K5Q7BNA2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Heron prices $150M common stock offering


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Heron prices $150M common stock offering

Heron Therapeutics Inc. priced an underwritten public offering of $150 million worth of common shares at $12.20 apiece.

The underwriters were given a 30-day option to buy an additional $22.5 million worth of common shares.

The issue is expected to close by Jan. 24.

The company intends to use the net proceeds for general corporate purposes, including the commercialization of Sustol and launch of Cinvanti.

BofA Merrill Lynch, Cowen and Co. LLC and Leerink Partners LLC are acting as joint book-running managers for the offering.

Cantor Fitzgerald & Co. and JMP Securities LLC are acting as lead managers while Noble Capital Markets, LifeSci Capital, Aegis Capital Corp. and Lake Street Capital Markets are acting as co-managers for the issue.